WallStSmart
PHAR

Pharming Group NV

NASDAQ: PHAR · HEALTHCARE · BIOTECHNOLOGY

$12.98
+8.17% today

Updated 2026-05-08

Market cap
$847.50M
P/E ratio
300.00
P/S ratio
2.29x
EPS (TTM)
$0.04
Dividend yield
52W range
$9 – $21
Volume
0.0M

WallStSmart proprietary scores

33
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+
6.3
Quality
B
4.0
Profitability
C
5.0
Valuation
C+
4/9
Piotroski F-Score
Moderate
1.5
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target
$34.60
+166.56%
12-Month target
$1.87
-85.59%
Intrinsic (DCF)
$18.40
Margin of safety
+15.38%
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Free cash flow $7.12M — positive
+ 15.38% below intrinsic value
Risks
- Altman Z 1.49 — distress zone
- Thin margins at 3.34%
- Revenue declining -8.40% QoQ
- P/E 300.00x — expensive valuation

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$205.62M$245.32M$297.20M$377.18M$369.49M
Net income$13.67M$-10.55M$-11.84M$2.86M$5.29M
EPS$0.04
Free cash flow$20.48M$-18.77M$-2.59M$49.31M$7.12M
Profit margin6.65%-4.30%-3.98%0.76%3.34%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PHAR$847.50M337.34.05.06.3+15.38%Avoid
LLY$869.41B7810.010.05.06.5Strong Buy
JNJ$535.63B594.79.03.36.0-38.45%Buy
ABBV$358.55B634.08.04.05.0-20.52%Buy
UNH$335.78B545.35.57.34.8+42.20%Buy
AZN$286.68B626.08.55.35.0+6.60%Buy

Smart narrative

Pharming Group NV trades at $12.98. representing a P/E of 300.00x trailing earnings. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.49, it sits in the distress. TTM revenue stands at $369.49M. with profit margins at 3.34%. Our DCF model estimates intrinsic value at $18.40.

Frequently asked questions

What is Pharming Group NV's stock price?
Pharming Group NV (PHAR) trades at $12.98.
Is Pharming Group NV overvalued?
Smart Value Score 33/100 (Grade F, Strong Sell). DCF value $18.40.
What is the price target of Pharming Group NV (PHAR)?
The analyst target price is $34.60, representing +166.6% upside from the current price of $12.98.
What is the intrinsic value of Pharming Group NV (PHAR)?
Based on our DCF model, intrinsic value is $18.40, a +15.4% margin of safety versus $12.98.
What is Pharming Group NV's revenue?
TTM revenue is $369.49M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
1.49 — distress.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio2.29x
ROE5.04%
Beta0.12
50D MA$16.28
200D MA$15.58
Shares out0.07B
Float0.73B
Short ratio
Avg volume0.0M

Performance

1 week-29.33%
1 month-29.33%
3 months-25.42%
YTD-32.09%
1 year
3 years
5 years